Today's news Industry groups seek to stem IP violations in China whereby China's IP enforcement efforts are being probed represents an interesting problem in a global environment.
Over the past several years, the Food & Drug Administration in the United States has been working closely to harmonize its efforts with drug approval agencies throughout the world. The goal is to prevent duplicated inspection and qualification efforts given the global focus of most drug companies today. The efforts benefit everyone and, for the most part, there is very little dissension.
Not so regarding IP. Patent rights, handling of claims, and collection of damages are all issues that can be extremely sticky depending on the countries involved and their relationship with each other.
There's little doubt something needs to be done to protect the rights of those who spend their valuable resources on R&D. What that will look like is the question.